BENTYL
LOE ApproachingNDAORALCAPSULE
Approved
May 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENTYL is an oral small-molecule capsule approved in 1950 for treating gastrointestinal conditions, likely an anticholinergic agent based on historical context and formulation. The exact mechanism of action and indications are not specified in available data, but the product remains in clinical use over 70 years post-approval.
$0.051MPart D
LOE ApproachingMinimal Medicare/Part D penetration ($51K annual spending) signals a niche, mature product with limited commercial growth potential and likely small, maintenance-focused team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BENTYL offers stable but limited career growth; this is a maintenance brand with minimal job openings and no pipeline expansion. Positions here suit candidates seeking operational expertise or GI specialty depth, but offer limited visibility for advancement into high-growth therapeutic areas.
Brand Manager (legacy maintenance)Field Sales (specialty/HCP relationship focus)
Worked on BENTYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.